In a patient with acute leukemia, immunophenotype pattern is CD 19+ve, CD 10+ve, CD33+ve, CD13+ve. He may probably have-
**Core Concept**
The immunophenotype pattern of CD19+ve, CD10+ve, CD33+ve, and CD13+ve in a patient with acute leukemia is indicative of a specific type of leukemia that can be further classified based on these markers.
**Why the Correct Answer is Right**
The presence of CD19 and CD10 suggests a B-cell lineage leukemia. CD19 is a pan-B-cell marker, and CD10 is often expressed in precursor B-cell acute lymphoblastic leukemia (B-ALL). The co-expression of CD33 and CD13, which are myeloid markers, can indicate a mixed lineage leukemia or a B-ALL with myeloid differentiation. This combination of markers is characteristic of B-ALL with myeloid features, previously known as acute undifferentiated leukemia (AUL) or mixed lineage leukemia (MLL).
**Why Each Wrong Option is Incorrect**
**Option A:** This option is not provided, so we will proceed with the remaining options.
**Option B:** This option is not relevant to the given immunophenotype pattern and would be incorrect based on the presence of myeloid markers (CD33 and CD13).
**Option C:** While B-ALL is a possibility with CD19 and CD10 positivity, the presence of myeloid markers (CD33 and CD13) makes this option less likely compared to a B-ALL with myeloid features.
**Clinical Pearl / High-Yield Fact**
When interpreting immunophenotype patterns in acute leukemia, remember that the presence of myeloid markers (e.g., CD33, CD13) in a B-cell lineage leukemia may indicate a B-ALL with myeloid features or mixed lineage leukemia.
**Correct Answer:** C. B-ALL with myeloid features